$9.05
0.98%
Nasdaq, Apr 25, 10:00 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$9.05
+0.92 11.32% 1M
-16.87 65.08% 6M
-10.12 52.79% YTD
-22.55 71.36% 1Y
-54.28 85.71% 3Y
-45.45 83.39% 5Y
-7.00 43.61% 10Y
Nasdaq, Closing price Fri, Apr 25 2025
-0.09 0.98%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $622.39m
Enterprise Value $-407.11m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -2.53
P/S ratio (TTM) P/S ratio 3.87
P/B ratio (TTM) P/B ratio 1.11
Revenue growth (TTM) Revenue growth 105.10%
Revenue (TTM) Revenue $161.00m
Cash position $1.04b
P/E forward negative
P/S forward 3.31
EV/Sales forward negative
Short interest 11.44%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Arvinas, Inc. forecast:

16x Buy
76%
5x Hold
24%

Analyst Opinions

21 Analysts have issued a Arvinas, Inc. forecast:

Buy
76%
Hold
24%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
161 161
105% 105%
100%
- Direct Costs 5 5
25% 25%
3%
161 161
124% 124%
100%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT - -
-
-
Net Profit -150 -150
59% 59%
-93%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
about 2 hours ago
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m.
Neutral
GlobeNewsWire
about 3 hours ago
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinic...
Neutral
GlobeNewsWire
5 days ago
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today